Although promoter mutations are known to cause functionally important consequences for gene expression, promoter analysis is not a regular part of DNA diagnostics.
Gene expression is regulated at many levels, including chromatin packing, histone modification, transcription initiation, RNA polyadenylation, pre-mRNA splicing, mRNA stability, and translation initiation. An important part of regulation, however, is believed to occur at the level of transcription initiation (1 ) . During the past few years, much progress has been made in understanding the basis of transcriptional regulation. Transcription factors (TFs), 1 chromatin-modifying enzymes, and TFs unite to activate genes and are recruited in a precise order to promoters. The timing of the activation of transcription and the ordered recruitment of factors to promoters are the engines that, at the right moment and for the right duration of time, drive transcriptional regulation of each gene throughout the cell's life-span (2 ) . Failure in timing or recruitment of TFs may affect transcriptional regulation of a gene, putatively leading to disease.
In this review we focus on sequence variations in the promoter region as a putative cause of disturbed transcriptional regulation leading to disease. Not every promoter sequence variation affects transcriptional regulation. Depending on the location and the nature of the genetic defect, a mutation in the promoter region of a gene may disrupt the normal processes of gene activation by disturbing the ordered recruitment of TFs at the promoter. As a result a promoter mutation can decrease or increase the level of mRNA and thus protein.
The effect of promoter mutations can be very subtle. In addition, promoter mutation analysis is complex, and the assays that are needed to investigate the functional relationship between the mutation and disease are laborious and difficult to perform. Therefore, thorough studies of promoter mutations are scarce and often confined to research laboratories.
THE PROMOTER OF A GENE
The promoter (Fig. 1) , a regulatory region of DNA located upstream of a gene, plays an important role in transcriptional regulation. The core promoter, a loosely defined region (approximate mean telomere signal Ϫ40 to ϩ50) surrounding the transcriptional start site (TSS), directs low-level transcription. The core promoter region contains binding sites for general TFs and RNA polymerase II. These general TFs, such as TFIID, TFIIA and TFIIB, assemble on the core promoter in an ordered fashion to form a transcriptioninitiation complex, which directs RNA polymerase II to the TSS (3 ). The core promoter may also contain other elements such as the TATA box, which is the binding site for a subunit of TFIID. This TATA box has the consensus-binding sequence 5Ј-TATAAA-3Ј and is characteristic for tissue-specific genes, the expression of which is restricted to a limited number of cells (4 ) . Housekeeping genes, the expression of which is ubiquitous, usually lack TATA boxes and instead contain GC-rich sequences.
The assembly of general TFs on the core promoter is sufficient to direct low levels of transcription, a process generally referred to as basal transcription. Transcriptional activity is greatly stimulated by a second class of TFs, termed activators. In general, activators are sequence-specific DNA-binding proteins whose recognition sites are present in the proximal promoter. The proximal promoter is the region immediately upstream, up to a few hundred base pairs, from the core promoter, and typically contains multiple binding sites for TFs (1 ) .
In contrast to the core and proximal promoter, enhancers are regulatory DNA sequences that may be located 5Ј or 3Ј to or within an exon or intron of a gene. Enhancer function is by definition independent of position and orientation. Enhancers are considered to act via a DNA-loop, whereby the enhancer and core promoter are brought into close proximity by "looping out" the intervening DNA (1 ) . Whereas there are common motifs in core and proximal promoters, enhancers do not contain many distinctive sequence motifs. Therefore they cannot easily be identified on the basis of their DNA sequence alone.
Sequence-specific elements that confer a negative (i.e., silencing or repressing) effect on the transcription of a target gene are called silencers. They generally have the same features as enhancers. In addition, the locus control region is a group of regulatory elements involved in regulating an entire locus or gene cluster. Locus control regions direct tissue-specific, physiological expression of a linked gene in a manner that is position independent and copy-number dependent and are composed of multiple cis-acting elements, including enhancers and silencers (1, 3 ) .
Many classes of TFs, which can be distinguished from each other by different DNA-binding domains, have been described. Examples of activator families include those containing a cysteine-rich zinc finger, homeobox, helix-loop-helix, basic leucine zipper, forkhead, or ETS DNA-binding domain (3 ) . The TFbinding sites (TFBS) are generally small, in the range of 6 -12 bp, although binding specificity is usually dictated by no more than 4 -6 positions within the site (1 ). The TFBS for a specific activator is therefore typically described by a consensus sequence in which certain positions are relatively constrained whereas others are more variable.
In September 2003, the National Human Genome Research Institute launched the ENCODE (encyclopedia of DNA elements) project to identify all functional elements in the human genome by using a mix of different experimental and computational approaches. During its pilot phase, the project focused on approximately 1% of the human genome sequence (ENCODE Project Consortium 2004: http:/www.genome.gov/ 10005107). One of the most surprising findings was that more than half of the genes use a tissue-specific and often unannotated set of exons outside the current boundaries of the annotated genes (5 ) . In some genes the promoters of other neighboring genes are used in specific cells and/or developmental stages. In addition, 5Ј untranslated regions have been shown to contain critical regulatory elements (6, 7 ) . These findings contribute to the opinion that transcriptional regulation is complex and therefore difficult to study.
LOCATION OF THE PROMOTER
To understand the mechanisms of transcriptional regulation of a certain gene, knowledge of the exact location of the promoter(s) and possible enhancers and silencers is necessary to relate promoter mutations to disease. In addition, this information is required to design correct promoter reporter vectors for transfection assays, the gold standard assay for investigating functional importance of promoter mutations (see below). Identifying the promoter of a specific gene poses a challenge, because core promoters are often located far upstream of the first coding exon. Furthermore, at least half of the mammalian genes are regulated by more than one promoter to enable tissue-specific regulation (8 ) . Fortunately, the promoters of many genes have recently been identified, and some of the most important TFBSs have been characterized (1 ) . Promoter prediction programs (e.g., PromoterInspector, FirstEF) may be used to identify and locate the promoter if this information is not available (Table 1) . These programs are frequently modified to make them more accurate and efficient.
It may be challenging to determine which region of the promoter should be screened for regulatory mutations. Recently, 5Ј untranslated regions have been shown to contain several critical regulatory elements (6 ) . Therefore it seems appropriate to start screening immediately upstream of the translation initiation site (which starts with the nucleotide sequence ATG). Evaluation of entries in the Human Gene Mutation Database (HGMD) (9 ) reveals that most registered regulatory mutations are located between nucleotides ϩ50 and Ϫ500 from the TSS of a gene. Rockman et al. (10 ) analyzed the distribution of functional singlenucleotide polymorphisms (SNPs) (see also below) in the human promoter region and showed that the first 500 nucleotides upstream of the TSS indeed contained most of the functional SNPs (59%). However, a sub- stantial fraction was found further upstream; 13% were more than 1 kb upstream, and another 13% were located 3Ј to the TSS. The authors even reported that 2 SNPs (1.4%) occurred even more than 10 kb upstream of their TSS. There is, therefore, a spatial distribution with respect to sequence variations affecting transcriptional regulation (10 ), although there is a bias toward the immediate 5Ј flanking sequence. These findings indicate that in case of a suspected regulatory mutation causing disease without alterations in the proximal or core promoter region, the upstream region is likely to be a good target for further analysis. Confirming this assumption are reports that mutations in upstream promoter regions, such as enhancers, silencers, and locus control regions, are associated with disease (11 ).
SIGNIFICANCE OF PROMOTER MUTATIONS IN HUMAN DISEASE PROMOTER MUTATIONS IN DISEASE
Some 1% of single base-pair substitutions causing human genetic disease occur within gene promoter regions, where they disrupt the normal processes of gene activation and transcriptional initiation and usually decrease or increase the amount of mRNA and thus protein (12 ) . Promoter mutations can alter or abolish the binding capacity of cis-acting DNA-sequence motifs for the trans-acting protein factors that normally interact with them (12 ) . Examples of promoter mutations causing disease include ␤-thalassemia, BernardSoulier syndrome, pyruvate kinase deficiency, familial hypercholesterolemia, and hemophilia (Table 2 ) (1 ). The contribution of promoter mutations to the total of disease-causing mutations is unclear, however. For instance, the majority of missense mutations cause a qualitative defect that is fairly easy to identify. Sometimes, mutant alleles even act as dominant alleles, because the affected protein may antagonize remaining normal protein.
In contrast, promoter mutations may cause small quantitative defects, which may be hard to detect. Even if the promoter of an autosomal gene is completely downregulated as result of mutation, half of the normal amount of protein is present, which is often enough to prevent severe disease.
Because there are few reports about the incidence of promoter mutations, we studied the HGMD (9, 13 ) . To date, this database contains a total of 73 411 registered mutations (assembly date September 2007), of which 1.5% are regulatory. An example of a thoroughly studied gene, which has been a model gene for studying mechanisms of transcriptional regulation, is the hemoglobin, beta (HBB) 2 gene. The HGMD database contains a total of 490 entries for HBB, of which 234 (48%) are missense/nonsense mutations, 28 (6%) promoter mutations, and 9 (2%) other (3Ј) regulatory mutations. The first regulatory mutation entry was that of a single base change (-28A3 C) in the TATA box of the HBB gene, which caused ␤-thalassemia in a Kurdish Jewish individual in 1982 (14 ) . This modification of the TATA box was the first ever found in association with a genetic disorder. Approximately 10 of 28 registered HBB promoter mutations have been studied by use of functional transfection assays (15 ) . An example of a gene in which regulatory mutations have only recently been identified is the cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (CFTR) gene. This gene was identified in 1989, and the catalogue of mutations now exceeds 1564 in number (www.genet.sickkids.on.ca/ cftr) but contains only 8 promoter mutations (0.52%). The first DNA defect, the well-known ⌬F508 deletion causing cystic fibrosis, was reported in 1989 (16 ), whereas Bienvenu et al. (17 ) reported the first regulatory mutation (-741T3 G) almost 6 years later. In contrast to HBB, only 1 of the 8 catalogued CFTR promoter mutations has been characterized by use of functional transfection assays (18 ) . Although the relevance of promoter mutations in cystic fibrosis is unknown, these observations suggest that the number of putative CFTR promoter mutations is underestimated. As in 2 Human genes: HBB, hemoglobin, beta; CFTR, cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7); GP1BB, glycoprotein 1b (platelet), beta polypeptide; PKLR, pyruvate kinase, liver and RBC; LDLR, low density lipoprotein receptor; F9, coagulation factor IX; PPOX, protoporphyrinogen oxidase. Reviews CFTR, promoter mutations may have been overlooked in other genes. As a result, it is difficult to assess the general incidence of disease-causing promoter mutations.
POLYMORPHIC PROMOTER SEQUENCE VARIATIONS IN DISEASE
In general, polymorphic sequence variations are considered to be rather harmless, especially if located in noncoding parts of a gene. The role of polymorphisms in determining susceptibility to disease traits is the subject of much research effort, but it often remains unclear whether the polymorphisms are themselves functionally relevant or just linked to another causative mutation (19 ) . The term polymorphism has been defined as a "Mendelian trait that exists in the population in at least two phenotypes, neither of which occurs at a frequency of Ͻ1%" (12 ) . Polymorphisms are not rare, being distributed thorough the human genome at a frequency of 1 in 200 to 1 in 1000 bp (20 ) . Polymorphisms that occur in the promoter may affect gene expression and may thus have the potential to be of phenotypic or even of pathological significance (12 ) . An increasing number of promoter polymorphisms have been characterized by functional studies. Some may well be pathologically important, e.g., those in the genes coding for plasminogen activator inhibitor type 1, tumor necrosis factor ␣, apolipoprotein AI, lipoprotein lipase, and interleukin 6 (12 ) . Current epidemiological investigations, in which large amounts of SNPs are studied in relation to disease, are revealing considerable numbers of putative functional promoter SNPs. However, a causal link between these promoter polymorphisms and disease is often absent, because these studies generally lack functional promoter assays. Without functional promoter assays it is incorrect to state that a certain promoter sequence variation causes disease in vivo; another regulatory mutation linked to the identified polymorphism may be the one affecting promoter activity, thereby causing disease.
TECHNIQUES FOR PROMOTER ANALYSIS IN SILICO ANALYSIS OF PROMOTER MUTATIONS
Literature and databases such as HGMD, National Center for Biotechnology Information Ensembl, and the online version of Mendelian Inheritance of Man can be used as a first step to investigate if an identified promoter sequence variation is known, associated with disease, and previously functionally characterized (Tables 1 and 3). DNA polymorphisms are often not catalogued in these databases unless they exhibit sufficiently strong phenotypic association (21 ) .
The next step is to use in silico analysis to investigate whether the sequence variation is disrupting or creating a putative TFBS (Table 3) . Experimental data regarding the specific binding sites of most wellcharacterized TFs have been compiled in databases such as TRANSFAC (Table 1 ) (22 ) . In these databases experimentally determined TFBSs are used to calculate a probability score for nucleotides on a specific position in a consensus TFBS (site matrix). Programs such as TESS (transcription element search software) (Table 1) (23 ) are able to compare a genomic sequence input to all matrices in TRANSFAC and report a list of potential TFBSs based on a statistical match between a region in the sequence and a site matrix. This analysis is, however, often encumbered by the prediction of a large number of putative TFBSs, a significant fraction of which will not be involved in transcriptional regulation of the gene. This situation may be attributable to the quality of the data used to build the TFBS matrices (24 ) and discrepancies that occur owing to in vivo absence or inactivity of a TF or cofactor, or to condensed local chromatin (25 ) . In addition to these false-positive problems, the comprehensiveness of the databases is also an issue; not all DNA-binding TFs have been identified, and even for some known factors, binding specificity has not yet been fully characterized (1 ) .
Phylogenetic footprinting (Table 3) , the comparison of the sequence of interest with the homologous region in other species, is used to investigate the putative functional relevance of a promoter sequence variation. The rationale behind this process is that nucleotides within binding sites are more likely to be conserved by natural selection. Although there is abundant evidence that conserved regions do, indeed, often contain functional regulatory motifs; this correlation does not always exist because not all TFBSs are conserved among species. Finally, some of the most important transcriptional regulatory elements relevant to normal human development and disease may not be highly conserved. Instead they may be restricted to only humans or primate relatives (1 ).
FUNCTIONAL PROMOTER ASSAYS
A promoter mutation that putatively causes disease must be characterized to assess the relevance of the DNA sequence variation in relation to the disease. Proper analysis demands proof that the mutation significantly alters promoter activity in vitro (functional assays, Table 3 ). One of the more versatile functional tests is based on the use of reporter gene assays. In these assays, the region of DNA to be tested for regulatory activity is cloned into a plasmid upstream of an easily assessable reporter gene, such as the genes coding for chloramphenicol acetyltransferase, ␤-galactosidase, green fluorescent protein, or luciferase (26 ) . The re- Reviews sulting wild-type and mutant constructs are then transfected (either transiently or stably) into cultured cells, and the activity of the reporter gene is measured to determine if the promoter mutation alters reporter gene expression (see for an example Fig. 2 ). Cotransfection of a control reporter plasmid is used to correct for transfection efficiency within or between transfection experiments. More sophisticated testing of upstream regulatory elements is performed by constructing transgenic organisms and monitoring reporter gene expression through the entire development of the organism (27 ) . Compared to constructing transgenic organisms, transient transfection assays are much easier to perform, less time-consuming, and more feasible in laboratories with only limited cell-culturing facilities. One of the restrictions is that regulatory elements can be widely dispersed and difficult to capture in a single reporter construct. Another concern is that the plasmid DNA is placed in an artificial environment, which may lead to inactivity or dysregulation of regulatory elements (19 ) . A third drawback is that the in vivo activity of a reporter gene may fail to reproduce the expression pattern of its endogenous equivalent owing to differences in chromatin context. Finally, a given upstream regulatory element may, in practice, be used only for restricted purposes, such as those specific for certain tissues or developmental stages. If the cell culture system used to assay the reporter gene activity does not match the physiological conditions under which the regulatory element is normally active, differences in promoter activity between wild-type and mutant constructs may not be detected (1 ) . Despite the limitations, reporter gene assays remain the most accurate means available to investigate the functional consequences of a promoter mutation.
DNA-TF-BINDING ASSAYS
In addition to functional promoter assays, it is essential to demonstrate that the interaction of a putative TF with the DNA sequence of interest is affected by the promoter mutation (DNA-TF-binding assays, Table  3 ) (28 ) . Several methods have been used for in vitro detection and characterization of protein-DNA interactions, including electrophoretic mobility shift assay (EMSA) and DNase I-footprinting assays (Table 3) . EMSA is by far the most commonly used assay, mainly because it provides a relatively simple, rapid, and extremely sensitive technique for the detection and characterization of specific protein-DNA interactions (29 ) . EMSA is based on the principle that a protein-DNA complex migrates more slowly through a native gel than the corresponding free DNA. Proteins within a nuclear extract that specifically recognize a given promoter sequence can be identified by incubating a small radiolabeled DNA probe with the extract to allow the formation of protein-DNA complexes. Application of the mixture to a native polyacrylamide gel and subsequent electrophoresis, will separate the free radiolabeled probe molecules from the protein-bound molecules (28 ) . Free DNA and DNA-protein complexes are then detected by autoradiography or phosphorimager analysis (Fig. 3) . Differences in binding pattern between the wild-type and mutant radiolabeled probes are indicative of TFs interacting with the DNA sequence of interest. Competition studies with nonlabeled wild-type and mutant competitor probes are used to test the specificity of DNA-protein interactions. Commercial kits for performing EMSA without the need for radiolabeled probes have recently become available. The putative TF candidate can be further identified by use of an antibody directed against this The -324T3 A mutation in the erythroid-specific promoter of the pyruvate kinase, liver and RBC (PKLR) gene does not affect promoter activity compared with the wild-type construct. In contrast, the -83G3 C strongly reduces in vitro promoter activity. We concluded that the -83G3 C mutation in the erythroid-specific promoter of PKLR strongly downregulates promoter activity in vitro (35 ) . This figure was taken from (35 ) .
protein. After electrophoresis, binding of this antibody to the DNA-protein complex results in a more slowly migrating or completely disappearing DNA-protein complex (supershift assay, Fig. 3 ). In case of an unknown protein interacting with the DNA sequence of interest, protein purification experiments must be performed first. One advantage of EMSA is that it is analytically sensitive and can reveal a specific protein-DNA complex even when the protein is present at low concentrations. A disadvantage is that the protein-DNA interaction has to be maintained during gel electrophoresis. Some protein-DNA complexes are not sufficiently strong to last during the typical 2-to 4-h electrophoresis time period. In addition, probes should be long enough to support the forming of stable protein-DNA interactions, and relatively large concentrations of nonspecific competitor DNA, such as poly(dI:dC), are often needed to increase specificity (28 ) .
Chromatin immunoprecipitation assays demonstrate the in vivo relevance of TF binding. In brief, in these assays growing cells are treated with formaldehyde to crosslink DNA-binding proteins to their target sites. Cells are then lysed, and the DNA is cleaved into fragments by digestion with a restriction enzyme or by ultrasonic shearing. Protein-DNA complexes are purified by immunoprecipitation with antibodies directed against the DNA-binding protein of interest. To determine whether the protein was crosslinked to the putative TFBS, antibody-binding is neutralized, proteins are digested by proteinase-K treatment, and DNA is analyzed by PCR for the presence of a DNA fragment encompassing the regulatory element (30 ) . The principal strength of the in vivo crosslinking assay is that it is the only method currently available for directly "visualizing" an in vivo interaction between a specific protein and a regulatory element (28 ) . A limitation of the approach is that it is technically challenging and that the putatively interacting TF must be known. The method requires high-quality antibodies capable of recognizing the fixed, target-bound TF, and optimization of chromatin-shearing conditions can be difficult. Fortunately, commercial chromatin immunoprecipitation assay kits have recently become available. These kits shorten optimization procedures, making these assays accessible for less experienced laboratories.
PROCEDURE FOR ANALYZING PROMOTER MUTATIONS AND

POLYMORPHISMS
In general, the characterization of a detected promoter variation can be performed according to the proposed standardized procedure displayed in Fig. 4 . This flowchart is compatible with most published promoter mutation studies. In silico analysis is relatively quick and easy and can also be performed by less experienced lab- Incubation of a wild-type (WT) protoporphyrinogen oxidase (PPOX) probe with K562 nuclear extract results in a specific DNA-protein complex (comp). This complex is absent in case of a GATA-1 mutated (mut) PPOX probe. The DNA-protein complex supershifts after addition of anti-GATA-1. We concluded that GATA-1 binds 1 of the GATA-binding motifs in exon 1 of PPOX in vitro (6 ). This figure was taken from (6 ). Different aspects of promoter analysis are put into a decision tree for characterization of promoter mutations and polymorphicpromoter sequence variations. ChIP, chromatin immunoprecipitation.
